FAST-CCT: Impact of Fast-rotation Coronary CT in Patients Undergoing Aortic Stenosis Workup

Sponsor
David C. Rotzinger (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05709652
Collaborator
(none)
124
2
24.1

Study Details

Study Description

Brief Summary

This study aims to evaluate the clinical value of a novel CT gantry supporting a .23 second rotation time and systematically compare it with 0.23 second rotation time, in patients with clinically indicated aortic CTA in the workup of aortic stenosis. Patients will be randomly assigned .23 or .28 sec rotation time CTA. Coronary artery interpretability rates will be determined in both groups.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Aortic CTA, .23s
  • Diagnostic Test: Aortic CTA, .28s
N/A

Detailed Description

Coronary artery analysis is an essential component of cardiac CT, but is often challenging without beta-blocker use. CT's technological advances are continuously evolving, paving the way for safer and more accurate diagnoses. Part of these innovations is the development of faster rotation speeds (0.23 sec/rotation), which is expected to allow for heart rate-independent CCTA.

Patients subjected to aortic stenosis workup routinely undergo invasive coronary angiography (ICA) in the catheterization laboratory, voiding the need to control the heart rate at the time of cardiac CT because aortic valve measurements can be performed even at higher heart rate. Still, cardiac CT in this context is performed with ECG-gating, and attempting to evaluate coronary arteries is possible without interfering with clinical decisions. Also, the existing literature advocates the use of gantry rotation speeds of at least 0.5 sec/rotation; consequently, the use of 0.28 versus 0.23 sec/rotation for this study will comply with current guidelines and will have no detrimental impact on patient management. This study aims to evaluate coronary artery interpretability in patients subjected to cardiac CT for the anatomical assessment of aortic valve stenosis prior to endovascular (transcatheter aortic valve implantation [TAVI]) or surgical therapy.

Patients will be enrolled after providing written, informed consent, and will be randomly assigned either to the test (0.23 sec rotation time) or control group (0.28 sec rotation).

The participants concerned are not subjected to any additional invasive or stressful procedure compared with those undergoing aortic stenosis workup in clinical routine.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
124 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Diagnostic
Official Title:
Impact of Fast Gantry Rotation Cardiac CT Angiography on Coronary Motion Artifacts in the Absence of β-Blocker Premedication in Patients Undergoing Aortic Stenosis Workup: a Single-centre Randomized Controlled Trial
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Mar 3, 2025
Anticipated Study Completion Date :
Mar 3, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental

Patients subjected to aortic CTA with a gantry revolution time of 0.23 sec

Diagnostic Test: Aortic CTA, .23s
Aortic CTA performed with short (0.23 sec) gantry rotation time.
Other Names:
  • GE Healthcare, Revolution Apex, cardiac and aortic CT angiography with 230 ms rotation time
  • Active Comparator: Control

    Patients subjected to aortic CTA with a gantry revolution time of 0.28 sec

    Diagnostic Test: Aortic CTA, .28s
    Aortic CTA performed with standard (.28 sec) gantry rotation time.
    Other Names:
  • GE Healthcare, Revolution Apex, cardiac and aortic CT angiography with 280 ms rotation time
  • Outcome Measures

    Primary Outcome Measures

    1. Interpretable CTA rate per patient [Up to 90 days]

      Number of patients with diagnostic image quality for coronary artery disease

    Secondary Outcome Measures

    1. Interpretable CTA rate, per segment [Up to 90 days]

      Number of segments with diagnostic image quality for coronary artery disease

    2. CTA performance to measure diameter stenosis, using invasive coronary angiography as gold standard [Coronary angiography performed withing 30 days of CTA]

      CTA's diagnostic accuracy for coronary occlusive disease

    3. Relationship between heart rate and non-diagnostic CTA [Up to 90 days]

      Correlation between of heart rate (in BPM) and the presence of any uninterpretable coronary segment on CTA

    4. Quantitative image quality (contrast to noise ratio) [Up to 90 days]

      Comparison of contrast to noise ratio between both groups

    5. Radiation dose per patient [Up to 90 days]

      Effective dose (mSv) comparison between both groups

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Subjected to cardiac CT due to known or suspected aortic valve stenosis
    Exclusion Criteria:
    • Patients unable to hold their breath, deaf or visually impaired

    • Estimated glomerular filtration rate (eGFR) of <30 mL/min

    • Hemodynamic instability or cardiogenic shock, Acute pulmonary edema, Exacerbated chronic obstructive pulmonary disease, Pregnant and breast-feeding women

    • Patients with prior coronary artery bypass grafting (CABG)

    • Patient incapable of discernment

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • David C. Rotzinger

    Investigators

    • Principal Investigator: David C. Rotzinger, MD, PhD, CHUV

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    David C. Rotzinger, MD, PhD, head of cardiovascular and thoracic radiology, University of Lausanne Hospitals
    ClinicalTrials.gov Identifier:
    NCT05709652
    Other Study ID Numbers:
    • BPR526
    First Posted:
    Feb 2, 2023
    Last Update Posted:
    Feb 2, 2023
    Last Verified:
    Jan 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by David C. Rotzinger, MD, PhD, head of cardiovascular and thoracic radiology, University of Lausanne Hospitals
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 2, 2023